Solvonis CEO: 'Strong tailwinds' for CNS as £1.3m fuels drug pipeline

yf_tkr_JNJ · 2026-08-25

$CNS $JNJ

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) CEO Anthony Tennyson spoke with Proactive's Stephen Gunnion about the company's £1.3 million fundraising and how proceeds will support its CNS pipeline, spanning SVN-001, SVN-002 and SVN-015. Tennyson said the funding will let Solvonis assess adding international sites to the Phase 3 programme for SVN-001, its severe alcohol use disorder treatment being trialled within the UK's NHS. Including EU sites and data could improve prospects for a European

Read the original at yf_tkr_JNJ ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.